[|I would change the title of this chapter to “Future Therapies” and fully agree that the most important aspect relating to future therapy is identification of antigenic triggers as was discussed early on in this book. I do believe this chapter should be significantly enlarged with full discussion on the new biologic therapies, both currently available and “in the pipeline”, eg anti-IL-12/23.|auteur215]

There are no anti-inflammatory, immunomodulatory or immunosuppressive drugs that have not been tried out in the general or topical treatment of psoriasis. Therapeutic hopes are high, therefore.

Better identify those who respond to the different treatments

This identification should be possible thanks to

  1. pharmacogenomic methods allowing identification of, on the one hand, individual response profiles to various types of environmental attacks and, on the other hand, the odds of responding to different treatments;
  2. the application of cluster classification methods to psoriasis, whereby homogenous groups of patients can be identified in clinical, biological, progressive and therapeutic terms.

SPIN Presentation


Follow us

The other websites of the foundation